VNN1 and metabolic dysfunction-associated steatotic liver disease: Recent study elucidated the role of Vnn1 in overactivation of gluconeogenesis, contributing to hyperglycemia [28], and our study also supports that Vnn1 may be a therapeutic target for NAFLD and associated glucose dysregulation.